Eli Lilly and Company(LLY) - Stock detail

Eli Lilly and Company

US
LLY
Eli Lilly and Company(Listing date: 07/09/1970)

Eli Lilly and Company was incorporated in Indiana in 1901, with its predecessor being a pharmaceutical manufacturing enterprise founded by Colonel Eli Lilly in Indianapolis, Indiana in 1876. The company develops, manufactures and markets important pharmaceutical products. Its mission is to combine "Caring" and "Discovery" to create better lives for people around the world.

🎯 Eli Lilly and Company (LLY) 💰 Analysis Report 📅 Generated: 2026-06-11 17:46:04 ET

Professional Trading Analysis: Eli Lilly and Company (LLY)

1. Investment Recommendation: SELL

2. Target Price: $1,025 (US Dollar)

  • Stop-loss price: $1,130 (immediate protection level)
  • Target sell price: $1,025 (3-month horizon)
  • Expected decrease: -11.7% from current price of $1,160.95

3. Confidence Level: 0.78

4. Risk Score: 0.65 (High Risk)

5. Detailed Reasoning

Valuation Extremes Justify Profit-Taking

  • Forward P/E of 91.43 represents bubble-level pricing that assumes perpetual hyper-growth acceleration
  • P/B ratio of 29.17 indicates extreme premium over tangible assets
  • P/S ratio of 15.13 suggests market has priced in all foreseeable positive developments
  • Historical precedent shows such extreme multiples inevitably contract, regardless of company quality

Technical Indicators Signal Exhaustion

  • RSI at 70.06 confirms overbought condition with high probability of near-term reversal
  • Price at $1,160.95 presses against upper Bollinger Band ($1,187.58), a classic reversal signal
  • 87% profit ratio among recent holders creates massive latent selling pressure
  • High ATR of 37.16 indicates extreme volatility that can rapidly reverse gains

Competitive Threats Underappreciated

  • Amgen’s MariTide (less frequent dosing) represents imminent competitive pressure
  • AstraZeneca’s GLP-1 pill development threatens Lilly’s market dominance
  • Employer pushback on GLP-1 coverage costs emerging as structural risk
  • Novo Nordisk’s current struggles demonstrate market’s unforgiving nature toward any stumble

Financial Leverage Amplifies Downside Risk

  • 73.24% Debt-to-Asset ratio creates vulnerability if growth moderates
  • High leverage magnifies pain during corrections despite current strong cash flow
  • In rising rate environment, debt servicing costs could pressure margins

Market Dynamics Favor Rotation

  • Stock has transformed from defensive healthcare name to high-momentum growth vehicle
  • Current technical setup favors profit-taking over new buying
  • Sector rotation out of extreme growth valuations likely as market seeks stability

Risk-Reward Profile Now Skewed Negative

  • Upside potential: ~10% to $1,300 (optimistic scenario, low probability)
  • Downside risk: ~25-30% to $850-950 (mean reversion scenario, higher probability)
  • Asymmetric risk profile favors selling into strength

Strategic Action Plan

  1. Immediate Action: Sell 50-70% of position to lock in substantial profits
  2. Remainder Management: Implement trailing stop at $1,130 to protect gains
  3. Re-entry Strategy: Wait for correction to $975-1,000 range (60-day MA support)
  4. Alternative: Consider short-dated put options to hedge remaining exposure

Conclusion: Eli Lilly and Company represents an extraordinary business executing flawlessly, but at $1,160.95, it represents a dangerously overvalued security. Prudent risk management dictates taking profits now and awaiting a more reasonable valuation entry point. The combination of extreme valuation, technical exhaustion, and emerging competitive threats creates an unfavorable risk-reward proposition for holders at current levels. ✅ Analysis Complete